Editorial
doi: 10.21037/jtd.2018.03.28.
Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century
Affiliations
- PMID: 29708166
- PMCID: PMC5906342
- DOI: 10.21037/jtd.2018.03.28
Item in Clipboard
Editorial
Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century
J Thorac Dis.
2018 Mar.
No abstract available
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Figures
Updated treatment algorithm for EGFR-mutated lung cancer. EGFR, epidermal growth factor receptor.
Comment on
-
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Clinical Trial.
Similar articles
-
[Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].Zhonghua Yi Xue Za Zhi. 2016 Dec 27;96(48):3870-3874. doi: 10.3760/cma.j.issn.0376-2491.2016.48.004. Zhonghua Yi Xue Za Zhi. 2016. PMID: 28057155 Chinese.
-
Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.Intern Med J. 2017 Dec;47(12):1405-1411. doi: 10.1111/imj.13555. Intern Med J. 2017. PMID: 28742280
-
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1. Lung Cancer. 2017. PMID: 29110841
-
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.Lung Cancer. 2018 Sep;123:70-75. doi: 10.1016/j.lungcan.2018.07.003. Epub 2018 Jul 4. Lung Cancer. 2018. PMID: 30089598
-
[Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].Gan To Kagaku Ryoho. 2014 May;41(5):533-8. Gan To Kagaku Ryoho. 2014. PMID: 24916999 Review. Japanese.
Cited by
-
Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation.RSC Adv. 2018 Nov 19;8(68):38733-38744. doi: 10.1039/c8ra06709k. eCollection 2018 Nov 16. RSC Adv. 2018. PMID: 35558335 Free PMC article.
-
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x. Target Oncol. 2018. PMID: 30284706
-
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.PLoS One. 2019 Apr 4;14(4):e0214598. doi: 10.1371/journal.pone.0214598. eCollection 2019. PLoS One. 2019. PMID: 30947315 Free PMC article.
-
Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.Oncologist. 2024 Oct 3;29(10):e1373-e1385. doi: 10.1093/oncolo/oyae050. Oncologist. 2024. PMID: 38558247 Free PMC article. Clinical Trial.
References
-
- Arrieta O, Guzman-de Alba E, Alba-Lopez LF, et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev Invest Clin 2013;65 Suppl 1:S5-84. - PubMed
-
- FDA. Erlotinib LABEL. Available onine: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lb...
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
